Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: April 27, 2017
Context: The Company filed a Japanese report ("Kessan Tanshin") with the Tokyo Stock Exchange containing financial results for the quarter ended March 31, 2017, and providing a financial forecast for the interim period ending June 30, 2017, and the full fiscal year ending December 31, 2017.
Key Financial Metrics and Guidance
The filing does not provide historical revenue, profit, cash flow, or debt figures for the quarter ended March 31, 2017, stating only that the Tanshin is substantially the same as the Form 10-Q. However, it provides the following forward-looking financial estimates:
| Period | Revenues | Operating Loss | Net Loss | Loss Per Share (Basic & Diluted) |
|---|---|---|---|---|
| Interim (6 months ending June 30, 2017) | $0 | $6,460,000 | $6,460,000 | $0.18 |
| Full Year (ending Dec 31, 2017) | $0 | $12,654,000 | $12,654,000 | $0.35 |
Note: Loss per share calculations assume a weighted average of 35,800,000 shares.
Material Changes and Prior Period Comparison
The filing text does not provide specific historical financial data for the prior comparable period (quarter ended March 31, 2016) or the current quarter (ended March 31, 2017) to calculate material changes in revenue, profit, or margins. The document serves primarily to disclose the forecasted losses for the upcoming periods.
Outlook, Risks, and Contingencies
- Forecast Basis: Estimates are based on management's assumptions regarding current conditions and trends. Actual results may differ materially.
- Auditor Disclaimer: Independent auditors have not compiled or reviewed the forecasted financial results and assume no responsibility for their accuracy.
- Key Risks:
- Regulatory approval delays or failures for product candidates.
- Delays in clinical trial enrollment or completion.
- Adverse side effects or inadequate therapeutic efficacy.
- Intellectual property challenges and patent validity.
- Ability to raise sufficient capital or debt financing.
- Market competition and economic conditions.
- Forward-Looking Statements: The report contains forward-looking statements subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the actual historical financial results for the quarter ended March 31, 2017, by reviewing the Form 10-Q referenced in the filing.
- Confirm the weighted average number of shares outstanding, as the forecast relies on a fixed assumption of 35,800,000 shares.
- Review the risk factors detailed in the Annual Report on Form 10-K for the year ended December 31, 2016, to understand potential deviations from the forecast.
- Monitor the Company's cash reserves and capital raising activities given the projected net losses and lack of revenue.